Delivery Order SPE2DB20D3111-SPE2DB25FA9AY
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,333.53 to AmerisourceBergen Drug Corp for Linzess 72 mcg capsules (30-count units) on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price delivery order was performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was competed among all eligible vendors in the open market. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp valued at $2,386.99 for the supply of Linzess 145 mcg capsules (30-unit quantity) with an ultimate completion date of August 5, 2025. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open procurement. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a $11,335.78 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Linzess 290 microgram capsules in quantities of 30 units. This firm fixed-price contract represents a competitively awarded, non-set-aside procurement with a completion date of August 19, 2025. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Linzess 72 mg capsules in a 30-count unit pack, with a contract ceiling value of $1,495.59 and an ultimate completion date of July 21, 2025. This firm fixed price delivery order represents a non-competitive award and is classified as a child contract under AmerisourceBergen's larger federal contracting framework. The performance location is the company's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $1,064.49 to AmerisourceBergen Drug Corp for Linzess 290 microgram capsules (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Linzess 72 mcg capsules (quantity: 30 units) valued at $2,112.00. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The contract has an ultimate completion date of July 25, 2025. This...
- The Defense Logistics Agency awarded a delivery order valued at $2,321.41 to AmerisourceBergen Drug Corp for the supply of Linzess 290 micrograms capsules (30-count units). This competitively awarded, firm fixed-price delivery order was executed on August 20, 2025, with an ultimate completion date of August 21, 2025. The contract represents a small-value pharmaceutical supply transaction fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,599.95 to AmerisourceBergen Drug Corp for the supply of LINZESS 145 MCG capsules (30-count units), with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Linzess 72 microgram capsules (30-count unit of use packaging) with a ceiling value of $1,155.69. This firm fixed-price delivery order, which is expected to be completed by August 15, 2025, represents a non-competitive set-aside award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $4,349.27 to AmerisourceBergen Drug Corp for the supply of Linzess 145 microgram capsules (30-count units) with an ultimate completion date of July 31, 2025. This competitive award, issued on July 30, 2025, utilizes firm fixed pricing with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location....
- SPE2DB20D3111Indefinite Delivery Contract
- SPE2DB20D3111-SPE2DB25FA9AYDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for LINZESS 145 MCG capsules (30-count units) with a ceiling value of $1,562.53. This non-set-aside, competitively awarded contract represents a firm fixed-price delivery order with an ultimate completion date of August 26, 2025. The award was issued on August 25, 2025, with performance to be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The underlying prime contract serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, has demonstrated capability to fulfill federal medical procurement requirements through its extensive portfolio of brand-name and generic medications across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 8/25/25 |